False negative results found in prognostic testing for breast cancer — ScienceDaily
source : http://www.sciencedaily.com/releases/2014/06/140618142612.htm
source : http://www.sciencedaily.com/releases/2014/06/140618142612.htm
The specific patient populations who appeared to benefit from eribulin, in comparison to capecitabine, are as follows: Patients with more than two organs involved with metastatic breast cancer Patients who had not received chemotherapy for six months or longer Patients who had received anthracycline and/or a taxane therapies in the metastatic setting Previous pre-specified exploratory analysis of overall survival and progression-free survival showed women with triple-negative, ER-negative, HER2-negative also had a greater relative benefit in overall survival with eribulin over capecitabine. …